CO-CSG
11.6.2019 14:02:05 CEST | Business Wire | Press release
As new digital services are deployed to help communications service providers (CSPs) drive innovation, 5G core networks are becoming a necessity to enable true service differentiation. This need is quickly becoming realized, with two-thirds of organizations1 planning to deploy 5G by the end of next year. Not only will CSPs be expected to deliver a fully functional 5G network to meet end-user demand, but success will lie in the ability to provide innovative digital services and to fully monetize their 5G infrastructure investment.
Today, CSG announced the availability of its new 5G Dynamic Charging Function, designed to help CSPs optimize their strategy to not only deliver the value of 5G networks to customers, but also to optimize for sustainable growth in the digital economy. This new capability fulfils the roles of both the 5G Charging Function (CHF) and the Charging Gateway Function (CGF), providing offline and online mediation functionality in a single platform, while managing the complexity of all interfaces between the network and the BSS functions.
“The revenue potential resulting from the deployment of 5G networks should not be underestimated,” said Chad Dunavant, global head of product management, CSG. “But the next generation of business, from 5G to the Internet of Things, requires fundamentally new businesses models. The CSG 5G Dynamic Charging Function gives CSPs the foundation they need to capitalize and monetize on complete industry transformation.”
The CSG 5G Dynamic Charging solution enables operators to:
- Drive service differentiation : Facilitate the monetization of network slicing, enabling charging of tenants and differentiated services by charging in-slice and across slices.
- Minimize risk and disruption to existing systems : Provides a cost effective and efficient way for service providers to seize the 5G opportunity.
- Elastically scale : Automatically scale up to process large charging volumes and down when traffic subsides to optimize infrastructure costs.
- Deliver unparalleled capacity : Process millions of transactions a second with low cost infrastructure to deploy.
- Automate operations : With intelligent tools for diagnostics and troubleshooting.
- Support critical services : Single-digit latencies for real-time online charging transactions.
- Be vendor independent : Support network functions and OSS/BSS systems from any vendor. Eliminates network equipment provider siloes.
- Preserve existing investments : Seamlessly manage the integration of service-based interfaces to existing online charging system interfaces for faster time to market.
With hundreds of global installations, CSG has one of the most trusted mediation and transaction management solutions in the world. CSG supports mediation across any domain, across all mediation functions, for all deployment approaches. The solution captures and processes customer usage events of all kinds from any service delivery network for industry leaders in digital communications and media, financial services, logistics and government.
For more information on how to effectively monetize 5G, download the latest CSG whitepaper here .
About CSG
CSG (NASDAQ: CSGS) is a provider of software and services that help companies around the world monetize and digitally enable the customer experience. For more than 35 years, CSG has simplified the complexity of business, providing revenue management and digital monetization, payments, and customer engagement solutions to help our customers tackle any business challenge and thrive in an ever-changing marketplace.
Operating across more than 120 countries worldwide, CSG manages billions of critical customer interactions annually. CSG is the trusted partner driving digital innovation for hundreds of leading global brands, including Arrow Electronics, AT&T, Charter Communications, Comcast, DISH, Eastlink, Formula One, iflix, MTN and Telstra.
To learn more, visit our website at csgi.com and connect with us on LinkedIn , Twitter and Facebook .
1 Gartner 5G Adoption Survey, December 2018
View source version on businesswire.com: https://www.businesswire.com/news/home/20190611005208/en/
Contact:
Brad Jones Public Relations CSG +1 (303) 200-3001 brad.jones@csgi.com Liz Bauer Investor Relations CSG +1 (303) 804-4065 liz.bauer@csgi.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 16:44:00 CET | Press release
One SKU. Every market. Connectivity decided at the end of production. Live at electronica 2026. Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the pr
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom